
Samara Master Fund Ltd - Form 8.3 - Mural Oncology Plc
PR Newswire
LONDON, United Kingdom, April 23
IRISH TAKEOVER PANEL
OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
TORONTO, April 23, 2025 --
1. KEY INFORMATION
(a) Full name of discloser | Samara Master Fund Ltd. |
(b) Owner or controller of interests and short The naming of nominee or vehicle companies |
|
(c) Name of offeror/offeree in relation to whose Use a separate form for each offeror/offeree | Mural Oncology Plc. |
(d) If an exempt fund manager connected with |
|
(e) Date position held/dealing undertaken For an opening position disclosure, state the | April 21, 2025 |
(f) In addition to the company in 1(c) above, is If it is a cash offer or possible cash offer, state "N/A" | NO |
2. INTERESTS AND SHORT POSITIONS
If there are interests and short positions to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2 for each additional class of relevant security.
Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)
(Note 2)
Class of relevant security |
| |||
| Interests | Short positions | ||
Number | % | Number | % | |
(1) Relevant securities owned and/or | 494,120 | 2.9 |
|
|
(2) Cash-settled derivatives |
|
|
|
|
(3) Stock-settled derivatives (including options) |
|
|
|
|
Total | 494,120 | 2.9 |
|
|
All interests and all short positions should be disclosed.
Details of options including rights to subscribe for new securities and any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8.
3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE (Note 4)
Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.
The currency of all prices and other monetary amounts should be stated.
(a) Purchases and sales
Class of relevant | Purchase/sale | Number of | Price per unit |
IE000LK2BOB4 | Purchase | 263,551 | $2.4646 |
IE000LK2BOB4 | Purchase | 155,569 | $2.4103 |
IE000LK2BOB4 | Purchase | 75,000 | $2.6278 |
(b) Cash-settled derivative transactions
Class of | Product | Nature of dealing | Number of | Price |
|
|
|
|
|
(c) Stock-settled derivative transactions (including options)
(i) Writing, selling, purchasing or varying
Class of | Product | Writing, purchasing, | Number | Exercise | Type | Expiry | Option |
|
|
|
|
|
|
|
|
(ii) Exercise
Class of | Product | Exercising/ | Number of | Exercise |
|
|
|
|
|
(d) Other dealings (including transactions in respect of new securities) (Note 3)
Class of | Nature of dealing | Details | Price per unit (if |
|
|
|
|
4. OTHER INFORMATION
(a) Indemnity and other dealing arrangements
Details of any indemnity or option arrangement, or any agreement Irrevocable commitments and letters of intent should not be included. |
|
(b) Agreements, arrangements or understandings relating to options or derivatives
Full details of any agreement, arrangement or understanding |
|
(c) Attachments
Is a Supplemental Form 8 attached? | NO | |
Date of disclosure | April 22, 2025 | |
Contact name | Ben Cubitt | |
Telephone number | 1 416 479 5408 | |
Public disclosures under Rule 8.3 of the Rules must be made to a Regulatory Information Service.
